A Phase 2 interventional study of Ceftriaxone and Placebo in Parkinson's Disease Dementia, sponsored by BrainX Corporation. Completed at 6 sites in Taiwan. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by BrainX Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.
Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 19th largest by enrollment of the 99 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 2, and was the 49th registered.
4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
Serina Therapeutics · Sites in Taiwan, United States, Australia
Ages 40–80
Hoffmann-La Roche · Sites in Taiwan, United States, Australia and 14 more countries
Ages 50–85
National Taiwan University Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 9 · Phase 4 2
First in 2005; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 40 across 3,358 interventional studies indexed under Parkinson Disease.
Median enrollment 55 across the 99 interventional studies, 92 across the 22 observational. Of the 58 that completed or were terminated, 9 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 121 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with BrainX Corporation as lead sponsor.
BrainX Corporation has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
11 of the studies in Parkinson Disease with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06548256Kaohsiung Medical University Chung-Ho Memorial HospitalThe Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease | 2026-12-31 |
| NCT07422675Serina TherapeuticsSAD Study in Patients With Parkinson's Disease and Motor Fluctuations | 2027-01-31 |
| NCT07172295National Taiwan University HospitalModulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With Refractory Hand Tremor. | 2027-06-30 |
| NCT07028515National Taiwan University HospitalSelf-controlled Practice on Motor Learning and Motivation in Parkinson's Disease | 2027-07-31 |
| NCT07294469Taipei Medical University HospitalMenthol for Improving Movement and Sleep in Parkinson's Disease Patients | 2027-07-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 121 studies in Parkinson Disease with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double blinded, placebo-controlled Phase II study to investigate the efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease dementia (PDD).This study will enroll approximately 106 patients to have up to 84 evaluable subjects, and conduct in Chung Shan Medical University Hospital, National Taiwan University Hospital, Kaohsiung Chang Gung Memorial Hospital, China Medical University Hospital, Changhua Christian Hospital, and Taipei Veterans General Hospital.
Parkinson's disease (PD) is a common neurodegenerative disorder that can cause significant disability and decrease quality of life. It is a chronic and progressive disease which means the symptoms become worse over time.
Parkinson's disease dementia (PDD) is a decline in thinking and reasoning that develops in many people living with PD at least a year after diagnosis. An estimated 50 to 80 percent of patients with PD eventually experience dementia as the disease progresses. Ceftriaxone is a kind of antibiotics, which has been marketed in many countries. This is the first time for ceftraxone treatment on PDD patient. The primary objective of this Phase II study is to evaluate the improvement of cognitive function in PDD patients with ceftriaxone administration.
This study will enroll approximately 106 patients, and conduct in multiple hospitals in Taiwan. Recruitment number of each site will be adjusted according to its enrollment status under the competitive enrollment model. Subjects will receive either ceftriaxone or placebo in a 1:1 ratio. One of the subjects' main caregiver should be involved to get the information of function of daily life and help to complete scale evaluation.
The study lasts about 33 weeks, during which eligible patients will be given 1 g/day/dose of ceftriaxone or placebo via injection 3 doses every cycle (2 weekly cycle), for a total of 16 cycles. And the subjects can choose to get injection either in the clinical site or in their house.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of PDD based on Movement Disorder Society (MDS) Task Force criteria as the following items:
All male and female patients with (between puberty and 2 years after menopause) should use at least any one of the appropriate methods shown below, for during and at least 4 weeks after ceftriaxone treatment.
d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.
Exclusion Criteria:
Patients with the following medications that could put patients at risk, interfere with study evaluations, or prevent meeting the requirements of the study at the judgement of PI should be excluded :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Name: Ceftriaxone 2. Dosage form: crystalline powder for intramuscular injection 3. Dose(s): 1 g 4. Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
Drug: Ceftriaxone
same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
Other: Placebo
1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
Also known as: Ceftriaxone Sandoz powder for IV Injection
Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
Compare the treatment difference in mean net change in ADAS-Cog score with time course
ADAS-Cog is a validated instrument to assess dementia covering memory, orientation, language, praxis and consisting of 11 items. The total possible scores range from 70 (severe impairment) to 0 (no impairment).
Time frame: from baseline to week 17 and 33 visits
Changes in Unified Parkinson's Disease Rating Scale (UPDRS) score
The UPDRS system is a composite scale intended for rating patients with PD. Scores are rated as 0-4 (0-1 for some Part IV), representing 0=normal and 1 or 4=maximal deficit, symptoms, or impairment.
Time frame: from baseline to week 17 and 33 visits
Changes in Judgment of Line Orientation score
The Judgment of Line Orientation (JLO) test is a widely used measure of visuospatial judgment. A score of 17 or less is considered a sign of severe deficit.
Time frame: from baseline to week 17 and 33 visits
Changes in Mini-Mental State Examination (MMSE) score
The MMSE is a brief, quantitative measure of cognitive status in adults. The instrument examines orientation, registration, attention, calculation, recall, visuo-spatial abilities and language. The maximum score is 30, with higher scores indicating better cognitive function.
Time frame: from baseline at week 17 and 33 visits
Changes in Clinical Dementia Rating (CDR) Scale score
The CDR Scale is a 5-point scale used to characterize 6 domains of cognitive and functional performance applicable to related dementias: memory, orientation, judgment \& problem solving, community affairs, home \& hobbies, and personal care. This score is useful for characterizing and tracking a patient's level of impairment/dementia with 0=normal, 0.5 =very mild dementia, 1=mild dementia, 2=moderate dementia, 3=severe dementia.
Time frame: from baseline to week 17 and 33 visits
Changes in Color Trail Test score
Color Trail Test provides quantitative and qualitative information by two trials. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
Time frame: from baseline to week 17 and 33 visits
Changes in MRI image for atrophy rate of brain
Multimodal MRI examinations will be performed on a 3T MRI scanner with a standard 8-channel head coil. Region of interest in the brain will be evaluated for functional changes including atrophy rate from baseline data.
Time frame: from baseline to week 17 and 33 visits
Changes in MRI image for dopaminergic projection from substantia nigra to striatum
Multimodal MRI examinations will be performed on a 3T MRI scanner with a standard 8-channel head coil. Region of interest in the brain will be evaluated for functional changes including dopaminergic projection from baseline data.
Time frame: from baseline to week 17 and 33 visits
Changes in Tc-99m TRODAT SPECT image
SPECT assessment will use Tc-99m, a radio tracer with high selectivity and specificity for the striatum dopamine transporter (DAT) density evaluation. DAT density change from baseline will be calculated from region of interest drawn in the striatum by independent readers.
Time frame: from baseline to week 17 and 33 visits
Net change of biomarker α-synuclein data
Patients' plasma samples will be collected to analyze α-synuclen by immunomagnetic reduction (IMR) assay kit developed by Magqu Company.
Time frame: from baseline to week 17 and 33 visits
Net change of biomarker Aβ42 data
Patients' plasma samples will be collected to analyze α-synuclen by immunomagnetic reduction (IMR) assay kit developed by Magqu Company.
Time frame: from baseline to week 17 and 33 visits
Plan to share: No
Ran from Feb 2019 to primary completion in Jul 2025, 77 months.
Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 77 months is above that.
Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceftriaxone